Recent research highlights a significant breakthrough in understanding colorectal cancer progression. Specifically, the study explores how cancer-associated fibroblasts (CAFs) communicate with tumor cells through exosomes. These exosomes carry oncogenic signals that fundamentally change how cancer cells behave and metabolize nutrients. This interaction within the tumor microenvironment appears critical for the advancement of the disease.

The Role of METTL1 in Colorectal Cancer Progression

Researchers found that exosomes derived from CAFs (CAFs-Exo) significantly increase the levels of METTL1 protein in colorectal cancer cells. METTL1 acts as a methyltransferase that facilitates N7-methylguanosine (m7G) modification. This specific modification stabilizes SLC1A5 mRNA, which serves as a key transporter for glutamine. By increasing the stability of this mRNA, the tumor cells produce more transporter proteins.

Furthermore, the team observed that this axis drives significant metabolic reprogramming. By increasing glutamine consumption, the cancer cells gain the energy and building blocks needed for rapid growth. Consequently, suppressing this pathway inhibited tumor growth and lung metastasis in animal models. Therefore, the METTL1/SLC1A5 interaction represents a promising therapeutic target for future clinical interventions in colorectal cancer progression.

Impact on Glutamine Metabolism

Glutamine metabolism serves as a vital fuel source for many aggressive tumors. This study demonstrates that CAFs-Exo promote glutamine consumption and the production of alpha-ketoglutarate. Moreover, identifying these molecular drivers helps clinicians understand tumor heterogeneity. This knowledge might eventually improve personalized treatment plans for patients with advanced colorectal cancer.

Additionally, the research highlights that silencing METTL1 can reverse the aggressive behaviors of cancer cells. When researchers reduced METTL1 expression, the cancer cells showed decreased migration and invasion. This discovery underscores the potential of targeting RNA modification enzymes to halt colorectal cancer progression effectively.

Frequently Asked Questions

How do exosomes from fibroblasts contribute to cancer?

Cancer-associated fibroblasts release exosomes that transport proteins and RNA to tumor cells. These molecules reprogram the cancer cells' metabolism and enhance their ability to grow and spread to other organs.

What is the clinical significance of METTL1?

METTL1 is an enzyme that modifies RNA to make it more stable. High levels of METTL1 are often linked to poor prognosis in colorectal cancer because they help the tumor cells survive and proliferate.

Can targeting glutamine metabolism stop tumor growth?

Yes, many tumors rely on glutamine for survival. By blocking transporters like SLC1A5 or the enzymes that stabilize them, researchers can effectively starve the cancer cells of essential nutrients.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Zhang S et al. Exosomes From Cancer-Associated Fibroblasts Promote Colorectal Cancer Progression and Glutamine Metabolism Through METTL1-Mediated m7G Modification of SLC1A5 mRNA. J Gastroenterol Hepatol. 2026 Mar 12. doi: 10.1111/jgh.70334. PMID: 41820224.

Chen J et al. METTL1-mediated m7G tRNA modification promotes colorectal cancer progression and liver metastasis via translational regulation. Cell Oncol. 2026;49(1):38. doi: 10.1007/s13402-025-01137-7.

Orellana EA et al. METTL1-mediated m7G modification of tRNA regulates cell cycle progression. Molecular Cell. 2021;81(5):951-964.e9. doi: 10.1016/j.molcel.2021.01.011.